Efficacy of antileukotriene agents in asthma management

Annals of Allergy, Asthma and Immunology

Volumn 86, Issue SUPPL. 1, 2001, Pages 9-17

  Nathan, Robert A ^a   Kemp, James P ^b  

^a Asthma & Allergy Associates PC and Research Center   (United States)

^b Asthma and Allergy Research Group and Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; ZAFIRLUKAST; ZILEUTON;

ASTHMA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG USE; HUMAN; MULTICENTER STUDY; NOSE CONGESTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY;

EID: 0034973079     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1081-1206(10)62306-x     Document Type: Conference Paper

References (42)

1. Pathology of asthma and its clinical implications
2. Leukotriene antagonists and synthesis inhibitors: New directions in asthma therapy
3. Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects
4. 2 to the nuclear envelope elicits topographically localized phospholipid hydrolysis
5. 5-Lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase
6. Prostanoid and leukotriene receptors: A progress report from the IUPHAR working parties on classification and nomenclature
7. 4, and histamine in normal human subjects
8. 4 and granulocytic infiltration into asthmatic airways
9. 4 in the human lung. Recruitment of neutrophils into the alveolar spaces without a change in protein permeability
10. 4 receptor antagonist ICI 204,219
11. 4-induced bronchoconstriction in subjects with asthma: A concentration-effect study of ICI 204,219
12. 4-induced bronchoconstriction in patients on maintenance inhaled corticosteroid therapy
13. 4 receptor antagonism in the airways of asthmatics
14. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin
15. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects
16. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma
17. Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects
18. Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma
19. 4 receptor antagonist
20. 4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist
21. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings
22. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: Bronchoalveolar lavage fluid findings after segmental antigen challenge
23. Zafirlukast for symptomatic mild-to-moderate asthma: A 13-week multicenter study
24. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial
25. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: A multicenter, randomized, double-blind trial
26. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial
27. An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses
28. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction
29. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics
30. Adverse effects of inhaled corticosteroids
31. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial
32. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients
33. Equivalence of adding zafirlukast versus double-dose inhaled corticosteroids in asthmatic patients symptomatic on low-dose inhaled corticosteroids
34. Improved asthma control over 6 weeks with Accolate (zafirlukast) in patients on high-dose inhaled corticosteroids
35. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid
36. A randomized controlled trial comparing zileuton with theophylline in moderate asthma
37. Montelukast compared to salmeterol in the treatment of exercise-induced asthma (EIA)
38. Effects of 13 weeks of treatment with ICI 204,219 (Accolate) or cromolyn sodium (Intal) in patients with mild to moderate asthma
39. 4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children
40. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma
41. Montelukast for chronic asthma in 6- to 14-year-old children: A randomized, double-blind trial